Membrane-bound proteins and receptor 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(JP2005508631) 受容​体​および​膜​結合​タンパク質
公开号/公开日
JP2005508631 A 2005-04-07 [JP2005508631] / 2005-04-07
申请号/申请日
2003JP-0530800 / 2002-07-16
发明人
Lal G Puriti;Forsyth Ian Jay;Chora Kay Narindar;Warren Brigitte Aiken;Sangaberu Kabisa;Ajimuzai Yarda;Lee Arne Steen Aye;Bogun Mariah Earl;Duggan Brendan M;Richardson Thomas AW;Elliott Vicky S;Bar manager Ze Dian I egane;Tran Kei Y;
申请人
INSIGHT GENOMICS;
主分类号
IPC分类号
A01K-067/00A01N-037/00A61K-038/00A61K-038/17A61K-039/00A61K-039/395A61K-045/00A61K-049/00A61P-001/00A61P-003/00A61P-003/06A61P-005/00A61P-009/00A61P-013/12A61P-021/00A61P-025/00A61P-029/00A61P-031/12A61P-035/00A61P-037/06C07H-021/04C07K-001/22C07K-014/00C07K-014/705C07K-016/18C07K-016/28C07K-016/46C12M-001/00C12M-001/34C12NC12N-001/15C12N-001/19C12N-001/21C12N-005/10C12N-015/09C12N-015/12C12P-021/02C12P-021/08C12Q-001/68G01N-015/00G01N-033/15G01N-033/50G01N-033/53G01N-037/00
摘要
(JP2005508631) Various embodiments of the invention provide human receptors and membrane-associated proteins (REMAP) and polynucleotides which identify and encode REMAP.  Embodiments of he invention also provide expression vectors, host cells, antibodies, agonists, and antagonists.  Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of REMAP.  (From WO03027228 A3)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2001US-60306020 2001-07-17 2001US-60308179 2001-07-27 2001US-60309702 2001-08-02 2001US-60311476 2001-08-10 2001US-60311551 2001-08-10 2001US-60311718 2001-08-10 2001US-60314798 2001-08-24 2001US-60316639 2001-08-31 2001US-60317996 2001-09-07 2002WO-US228
主权利要求
(JP2005508631) 1. (G) of less than or equal to (a) is selected from the group consisting of the isolated polypeptide. (a) SEQ ID NO:1-23 from the group consisting of (10 to SEQ ID NO:1) polypeptide comprising the amino acid sequence selected from (b) SEQ ID NO:1-4, SEQ ID NO:6-10, SEQ ID NO:12-14, SEQ ID NO:19-23 and SEQ ID NO:17 selected from the group consisting of an amino acid sequence that is at least 90% identical to the naturally occurring amino acid sequence SEQ ID NO:18 (c) a polypeptide comprising the amino acid sequence at least 91% identical to the amino acid sequence of the naturally occurring (d) a polypeptide having 92% is the same as the amino acid sequence of SEQ ID NO:11 such that at least a polypeptide having an amino acid sequence of SEQ ID NO (e) naturally occurring: 5 is the same as the amino acid sequence at least 94% polypeptide having the amino acid sequence of a naturally occurring amino acid sequence of SEQ ID NO:16 (f) at least 98% native amino acid sequence is identical to the amino acid sequence of SEQ ID NO:15 (g) a polypeptide having at least 99% identical to the naturally occurring polypeptide comprising an amino acid sequence SEQ ID NO (h): 1-23 selected from the group consisting of a polypeptide having the amino acid sequence of a biologically active fragment thereof, and (i) SEQ ID NO:1-23 is selected from the group consisting of an immunogenic fragment of a polypeptide having the amino acid sequence of  2. SEQ ID NO:1-23 and selected from the group consisting of the amino acid sequences, the isolated polypeptide according to claim 1.  3. An isolated polynucleotide encoding a polypeptide according to claim 1.  4. An isolated polynucleotide encoding a polypeptide according to claim 2.  5. A polynucleotide sequence selected from the group consisting SEQ ID NO:24-46 comprising, the isolated polynucleotide according to claim 4.  6. Operably linked to the polynucleotide according to claim 3 and recombinant polynucleotide includes a promoter sequence.  7. Using the recombinant polynucleotide according to claim 6 transformed cells.  8. Comprising a recombinant polynucleotide according to claim 6 genetic transformants.  9. Claim 1 method of producing the polypeptide of, expression of said polypeptide (a) under suitable conditions, a polynucleotide encoding a polypeptide of claim 1 operably linked to a promoter sequence linked to the recombinant cell culture transformed with the polynucleotide and the processes, such as (b) recovering the polypeptide expressed from method step.  10. Said polypeptide comprising, SEQ ID NO:1-23 is selected from the group consisting of an amino acid sequence including said, method according to claim 9.  11. That specifically binds to a polypeptide according to claim 1 isolated antibody.  12. (G) of less than or equal to (a) has been selected from the group consisting of the isolated polynucleotide. (a) A polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46 polynucleotide that comprises (b) a polynucleotide sequence selected from the group consisting of SEQ ID NO:24-46 is at least 90% identical to the polynucleotide comprising the polynucleotide sequence of a natural (a) the polynucleotide of (c) a polynucleotide complementary to the polynucleotide of (d) a polynucleotide complementary to (b) (a) - (e) the RNA equivalent of a (d)  13. At least 60 consecutive nucleotides of a polynucleotide according to claim 12 comprising the isolated polynucleotide.  14. A target polynucleotide having a sequence of a polynucleotide according to claim 12 detection method in a sample, said target polynucleotide in the sample (a) a sequence that is complementary to at least 20 consecutive nucleotides of the sample with a probe having a hybridizing step, wherein (b) detecting the presence or absence of a hybridization complex, optionally in the presence of the complex is the quantity sensing method comprising.  15. Wherein the probe comprises at least 60 consecutive nucleotides of the method according to claim 14 wherein.  16. Having the sequence of a polynucleotide according to claim 12 detected from the target polynucleotide in the sample the method comprising, using the polymerase chain reaction amplification (a) said target polynucleotide or fragment thereof of the procedure of amplification, wherein amplified (b) detecting the presence of the target polynucleotide or fragment thereof and, wherein said target polynucleotide or fragment thereof that is optionally in the presence of the detection of the amount characterized in that the method comprises the step.  17. And a polypeptide according to claim 1, and the pharmaceutically acceptable composition comprising an excipient.  18. Said polypeptide comprising, SEQ ID NO:1-23 is selected from the group consisting of an amino acid sequence characterized in that, the composition of claim 17.  19. Disorders associated with decreased expression of functional REMAP or method to treat a disease state, to a patient in need of such treatment a composition according to claim 17 characterized in that the method comprises the step.  20. Claim 1 as agonist of the polypeptide for the validation of a method of screening compounds, comprising the polypeptide of claim 1 (a) exposing a sample compound, (b) detecting agonist activity in the sample characterized in that the method comprises the step.  21. And a compound identified by the method according to claim 20 agonists, including pharmaceutically acceptable excipients characterized in that the composition.  22. The decreased expression of functional REMAP in the treatment of a disease or condition associated with the method, to a patient in need of such treatment comprising administering the composition of claim 21 characterized in that the treatment method.  23. As an antagonist of a polypeptide according to claim 1 in order to check the effectiveness of the method for screening compounds, comprising the polypeptide of claim 1 (a) exposing a sample compound, (b) detecting antagonist activity in said sample wherein the method comprises a step.  24. And an antagonist compound identified by the method according to claim 23, and the pharmaceutically acceptable composition comprising an excipient.  25. Associated with the expression of functional REMAP in excess of the method for treating a disease or condition, to a patient in need of such treatment a composition according to claim 24 characterized in that the method comprises the step.  26. Claim 1 for screening for compounds that bind specifically to the polypeptide of claim method of, claim 1 (a) at least one polypeptide of claim 1 under conditions suitable for the mixing of the test compound, the polypeptide of claim 1 (b) detecting the binding of the test compound, that bind specifically to the polypeptide of claim 1 thereby identifying a compound that comprises the step of the method.  27. A compound that modulates the activity of a polypeptide according to claim 1 screening method, of claim 1 (a) under conditions permissive for the activity of the polypeptide, at least one polypeptide of claim 1 1 and mixing of the test compound, the activity of a polypeptide according to claim 1 (b) in the presence of the test compound and calculating step, (c) in the presence of the test compound according to claim 1 activity of the polypeptide of, in the absence of the test compound as compared to the activity of a polypeptide according to claim 1 of comprises a course, in the presence of the test compound changes the activity of the polypeptide according to claim 1, a compound that modulates the activity of a polypeptide according to claim 1 and marking method.  28. Claim 5 target polynucleotide having a sequence that is effective to alter expression of the method for screening a compound, said target polynucleotide in the expression of (a) under suitable conditions, said target polynucleotide and a sample comprising the compounds and processes, said target polynucleotide (b) detecting altered expression of the course, (c) in the presence of varying amounts of the compound in the absence of the compound wherein the expression of the polynucleotide target comprises a comparison of said processes.  29. To assess the toxicity of a test compound in the method, in a biological sample containing nucleic acid (a) said test compound and the treating step, (b) processing the biological sample with a nucleic acid, at least 20 contiguous nucleotides of a polynucleotide of claim 12 probe having a hybridizing causing a, this Hybridization internalization is, wherein the probe and a target polynucleotide in the biological sample with the specific hybridization is performed under conditions in which a complex is formed, said target polynucleotide, the polynucleotide or fragment thereof of claim 12 polynucleotide comprising the polynucleotide sequence, and wherein the step, (c) quantifying the hybridization complexes with a yield of course, (d) processing said biological sample the amount of complex in the hybridized thailand internalization, processing has not been hybridized thailand internalization of the complex in the biological sample compared to the amount of comprises the step, in a biological sample for processing said hybridized thailand internalization of the difference between the amount of complex, wherein the toxicity of a test compound in such a manner that the indicia.  30. Associated with the expression of REMAP in a biological sample for diagnosis of a condition or disease in the test method, according to claim 11 (a) the antibody and the biological sample mixture, wherein the antibody binds to said polypeptide, antibody and forms a complex with the polypeptide under conditions suitable for the processes, (b) comprises the detecting of the complex, wherein presence of the complex of, wherein the polypeptide in the biological sample can be correlated with the presence of said.  31. The antibody according to claim 11, (a) a chimeric antibody Fab a single chain antibody (c) (ab ') fragment (d) F2 (e) a humanized antibody fragment of any one of the antibodies.  32. An antibody according to claim 11, a composition comprising an acceptable excipient.  33. The expression of REMAP in a subject of a condition or disease associated with a diagnostic method, wherein the effective amount of a composition according to claim 32 administered to the subject wherein the method comprises the step.  34. Wherein the antibody is labeled with a composition according to claim 32.  35. The expression of REMAP in a subject of a condition or disease associated with a diagnostic method, wherein the effective amount of a composition according to claim 34 administered to the subject wherein the method comprises the step.  36. Having the specificity of the antibody according to claim 11 method of preparing a polyclonal antibody, under conditions to elicit an antibody response (a), SEQ ID NO:1-23 the amino acid sequence selected from the group consisting of a polypeptide comprising a fragment or immunogenic immunizing animal using the course, (b) isolating the antibodies from said animal and in the course of, (c) said isolated antibody polypeptide screened, whereby, SEQ ID NO:1-23 in the amino acid sequence selected from the group consisting of polyclonal antibodies which bind specifically to a polypeptide comprising a method to identify a course.  37. Claim 36 polyclonal antibody produced by the method of.  38. Claim 37 and the polyclonal antibody composition with a suitable carrier.  39. A monoclonal antibody having the specificity of the antibody according to claim 11 method sGFP, (a) under conditions to elicit an antibody response, SEQ ID NO:1-23 the amino acid sequence selected from the group consisting of a polypeptide comprising a fragment or immunogenic immunizing animal using the processes, producing antibodies from said animal (b) isolating the cells, immortalized cells producing said antibody (c) a fusion cell, hybridoma cell line producing a monoclonal antibody and forming, in said culturing the hybridoma cells and course, (e) SEQ ID NO:1-23 is selected from the group consisting of a polypeptide comprising amino acid sequence as said monoclonal antibodies bind specifically to the isolated from culture characterized in that the method comprises the step and the.  40. A monoclonal antibody produced by a method according to claim 39.  41. The monoclonal antibody according to claim 40 composition comprising a suitable carrier.  42. Fab is produced by screening a library of the expression of said antibody according to claim 11.  43. The antibody of claim by screening a recombinant immunoglobulin of said antibody and the antibody according to claim 11 hectares.  44. SEQ ID NO:1-23 is selected from the group consisting of a polypeptide comprising the amino acid sequence detection method, according to claim 11 antibody and said polypeptide of (a) under conditions that allow specific binding, wherein the 1 antibody and the sample and incubating step, and the detecting of (b) comprises specific binding, the binding SPUs matching, SEQ ID NO:1-23 amino acid sequence selected from the group consisting of a polypeptide having indicia is present in the sample to be characterized.  45. SEQ ID NO:1-23 in the amino acid sequence selected from the group consisting method comprising purification of the polypeptide, said polypeptide with an antibody according to claim 11 (a) under conditions that allow specific binding, and incubating the sample with the antibody and 1 in the course of, (b) separating the antibody from the sample, SEQ ID NO:1-23 amino acid sequence selected from the group consisting of a purified polypeptide comprising the method comprising the procedure of.  46. 1 At least one element of the microarray is a polynucleotide according to claim 13 characterized in that the micro-array.  47. An expression profile of a sample comprising a polynucleotide prepared by the method comprising, in a sample of a polynucleotide of (a) in the course of labeled hybridization complex (b) under conditions suitable for the formation of the elements of the microarray of claim 46 labeled polynucleotide in the sample and the contacting step, in the sample in the expression of a polynucleotide of (c) quantifying the method comprises the step of  48. A certain physical position on a solid substrate attached to a unique nucleotide molecules in the array having a variety of, at least one of said nucleotide molecule is 1, at least some of the 30 consecutive nucleotides of the target polynucleotide to hybridize specifically to a group capable of having a first oligonucleotide or polynucleotide sequence, said target polynucleotide is a polynucleotide and the array according to claim 12.  49. An array according to claim 48, wherein said first oligonucleotide or polynucleotide sequence is at least 30 of said target polynucleotide that is fully complementary to contiguous nucleotides in said array.  50. An array according to claim 48, wherein said first oligonucleotide or polynucleotide sequence is at least 60 said consecutive nucleotides of the target polynucleotide is completely complementary to said array.  51. An array according to claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to a target polynucleotide of said array.  52. An array according to claim 48, characterized in that the array is a microarray.  53. An array according to claim 48, wherein said first oligonucleotide or polynucleotide has a sequence of nucleotide molecules hybridizing to a target polynucleotide of said array and further comprising.  54. An array according to claim 48, wherein at least some of the linker with a respective one of the nucleotides of the 1 molecule is coupled to a solid substrate and the array.  55. An array according to claim 48, unique physical location on the substrate and each of the plurality comprise nucleotide molecules, and any single of the plurality of unique physical locations have a sequence identical to the nucleotide molecule is, on the substrate of each of the unique physical location, on the substrate in another unique physical location differs from the sequence of nucleotide molecules having a sequence comprising a nucleotide molecules and the array.  56. SEQ ID NO:1 comprises the amino acid sequence of the polypeptide according to claim 1.  57. SEQ ID NO:2 comprises the amino acid sequence of the polypeptide according to claim 1.  58. SEQ ID NO:3 comprises the amino acid sequence of the polypeptide according to claim 1.  59. SEQ ID NO:4 comprises the amino acid sequence of the polypeptide according to claim 1.  60. SEQ ID NO:5 comprises the amino acid sequence of the polypeptide according to claim 1.  61. SEQ ID NO:6 comprises the amino acid sequence of the polypeptide according to claim 1.  62. SEQ ID NO:7 comprises the amino acid sequence of the polypeptide according to claim 1.  63. SEQ ID NO:8 comprises the amino acid sequence of the polypeptide according to claim 1.  64. SEQ ID NO:9 comprises the amino acid sequence of the polypeptide according to claim 1.  65. A polypeptide comprising the amino acid sequence of SEQ ID NO:10 according to claim 1.  66. A polypeptide comprising the amino acid sequence of SEQ ID NO:11 according to claim 1.  67. A polypeptide comprising the amino acid sequence of SEQ ID NO:12 according to claim 1.  68. A polypeptide comprising the amino acid sequence of SEQ ID NO:13 according to claim 1.  69. A polypeptide comprising the amino acid sequence of SEQ ID NO:14 according to claim 1.  70. A polypeptide comprising the amino acid sequence of SEQ ID NO:15 according to claim 1.  71. A polypeptide comprising the amino acid sequence of SEQ ID NO:16 according to claim 1.  72. A polypeptide comprising the amino acid sequence of SEQ ID NO:17 according to claim 1.  73. A polypeptide comprising the amino acid sequence of SEQ ID NO:18 according to claim 1.  74. A polypeptide comprising the amino acid sequence of SEQ ID NO:19 according to claim 1.  75. A polypeptide comprising the amino acid sequence of SEQ ID NO:20 according to claim 1.  76. A polypeptide comprising the amino acid sequence of SEQ ID NO:21 according to claim 1.  77. A polypeptide comprising the amino acid sequence of SEQ ID NO:22 according to claim 1.  78. A polypeptide comprising the amino acid sequence of SEQ ID NO:23 according to claim 1.  79. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:24 according to claim 12.  80. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:25 according to claim 12.  81. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:26 according to claim 12.  82. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:27 according to claim 12.  83. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:28 according to claim 12.  84. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:29 according to claim 12.  85. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:30 according to claim 12.  86. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:31 according to claim 12.  87. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:32 according to claim 12.  88. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:33 according to claim 12.  89. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:34 according to claim 12.  90. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:35 according to claim 12.  91. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:36 according to claim 12.  92. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:37 according to claim 12.  93. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:38 according to claim 12.  94. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:39 according to claim 12.  95. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:40 according to claim 12.  96. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:41 according to claim 12.  97. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:42 according to claim 12.  98. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:43 according to claim 12.  99. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:44 according to claim 12.  100. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:45 according to claim 12.  101. A polynucleotide comprising the polynucleotide sequence of SEQ ID NO:46 according to claim 12.
法律状态
(JP2005508631) LEGAL DETAILS FOR JP2005508631  Actual or expected expiration date=2014-04-07    Legal state=DEAD    Status=LAPSED     Event publication date=2002-07-16  Event code=JP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=JP JP2003530800  Application date=2002-07-16  Standardized application number=2003JP-0530800     Event publication date=2005-04-07  Event code=JP/A  Event indicator=Pos  Event type=Examination events  Published application  Publication country=JP  Publication number=JP2005508631  Publication stage Code=A  Publication date=2005-04-07  Standardized publication number=JP2005508631     Event publication date=2014-04-07  Event code=JP/EEDL  Event indicator=Neg  Event type=Event indicating Not In Force  Pending application likely abandoned
专利类型码
A
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部